Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

医学 内科学 丙型肝炎 丙型肝炎病毒 人口 免疫学 病毒 环境卫生
作者
Jason Grebely,Gregory J. Dore,Frederick L. Altice,Brian Conway,Alain H. Litwin,Brianna L. Norton,Olav Dalgård,Edward Gane,Oren Shibolet,Ronald Nahass,Anne F. Luetkemeyer,Cheng‐Yuan Peng,David Iser,Isaias Noel Gendrano,Michelle M. Kelly,Peggy Hwang,Ernest Asante‐Appiah,Barbara Haber,Eliav Barr,Michael Robertson,Heather Platt
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:175 (9): 1221-1229 被引量:9
标识
DOI:10.7326/m21-4119
摘要

Background: Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. Objective: To evaluate the rate of HCV reinfection for 3 years after successful treatment among people receiving opioid agonist therapy (OAT). Design: A 3-year, long-term, extension study of persons enrolled in the CO-STAR (Hepatitis C Patients on Opioid Substitution Therapy Antiviral Response) study (ClinicalTrials.gov: NCT02105688). Setting: 55 clinical trial sites in 13 countries. Patients: Aged 18 years and older with chronic HCV infection with genotypes 1, 4, or 6 receiving stable OAT. Intervention: No treatments were administered. Measurements: Serum samples were assessed for HCV reinfection. Urine drug screening was performed. Results: Among 296 participants who received treatment, 286 were evaluable for reinfection and 199 were enrolled in the long-term extension study. The rate of HCV reinfection was 1.7 [95% CI, 0.8 to 3.0] per 100 person-years; 604 person-years of follow-up). A higher rate of reinfection was seen among people with recent injecting drug use (1.9 [95% CI, 0.5 to 4.8] per 100 person-years; 212 person-years). Ongoing drug use and injecting drug use were reported by 59% and 21% of participants, respectively, at the 6-month follow-up visit and remained stable during 3 years of follow-up. Limitations: Participants were required to be 80% adherent to OAT at baseline and may represent a population with higher stability and lower risk for HCV reinfection. Rate of reinfection may be underestimated because all participants did not continue in the long-term extension study; whether participants who discontinued were at higher risk for reinfection is unknown. Conclusion: Reinfection with HCV was low but was highest in the first 24 weeks after treatment completion and among people with ongoing injecting drug use and needle–syringe sharing. Primary Funding Source: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wldsd发布了新的文献求助30
1秒前
充电宝应助王羊补牢采纳,获得10
4秒前
科研通AI2S应助酷酷飞烟采纳,获得10
4秒前
meng发布了新的文献求助30
5秒前
5秒前
完美小蘑菇完成签到,获得积分10
5秒前
兰是一个信仰完成签到,获得积分10
5秒前
潇湘雪月发布了新的文献求助10
8秒前
YJ888发布了新的文献求助10
8秒前
azusa完成签到,获得积分10
12秒前
昔年若许完成签到,获得积分10
19秒前
22秒前
23秒前
25秒前
高手发布了新的文献求助10
25秒前
善学以致用应助1WSQARFGRDSX采纳,获得10
26秒前
ZZZ完成签到,获得积分10
27秒前
ZZZ发布了新的文献求助10
29秒前
一一完成签到 ,获得积分10
29秒前
hp发布了新的文献求助10
31秒前
32秒前
姚世娇完成签到 ,获得积分10
34秒前
FashionBoy应助高手采纳,获得10
35秒前
meng完成签到,获得积分10
36秒前
chennn完成签到,获得积分10
36秒前
38秒前
39秒前
晗月完成签到,获得积分10
39秒前
情怀应助如意枫叶采纳,获得10
40秒前
量子星尘发布了新的文献求助10
42秒前
Akim应助SS采纳,获得10
43秒前
张雷应助清新的夜蕾采纳,获得20
43秒前
chennn发布了新的文献求助10
43秒前
罗一完成签到,获得积分10
45秒前
47秒前
丘比特应助wu采纳,获得10
50秒前
俏皮芷蕊发布了新的文献求助30
50秒前
称心的菲鹰完成签到,获得积分10
51秒前
碧蓝问安发布了新的文献求助10
52秒前
52秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136